Merck & Co., Inc. (MRK) rises on lung cancer trial win
May 22, 20266 min read
Key Takeaway
Merck & Co., Inc. (MRK) rises 5.1% after positive Phase 3 lung cancer data showed improved progression-free and overall survival for a Keytruda combination. The result reinforces Merck’s oncology growth story and suggests the company can extend Keytruda’s runway, which is a bullish signal for investors despite the stock already trading near its 52-week high.
Merck & Co., Inc. (MRK) rises sharply today after a late-stage lung cancer trial delivered the kind of result biotech investors care about most: better survival. The move matters because Merck is already trading near its 52-week high, so a 5.14% gain to $121.84 stands out as a meaningful repricing of its oncology growth story.
Key Takeaways
•
MRK is up 5.14% today to $121.84, a strong move for a low-beta healthcare stock with a 0.195 beta.
•
The clearest catalyst is Merck’s May 21 Phase 3 OptiTROP-Lung05 update, where sacituzumab tirumotecan plus Keytruda improved progression-free survival and overall survival versus Keytruda alone in advanced or metastatic non-small cell lung cancer.
•
That trial result matters because Keytruda and Keytruda Qlex generated $8.0B in Q1 2026 sales, up 12% year over year, making oncology the center of the Merck investment case.
•
Merck reported Q1 2026 companywide sales of $16.3B, up 5%, and raised its 2026 sales outlook to $65.8B to $67.0B with non-GAAP EPS guidance of $5.04 to $5.16.
•
For investors, today’s rally points to renewed confidence that Merck can extend the Keytruda franchise through combination therapies instead of leaning on a single blockbuster alone.
Why Merck Stock Rises Today on Phase 3 Lung Cancer Data
The most likely reason Merck stock rises today is straightforward: positive Phase 3 data in lung cancer. On May 21, Merck said the OptiTROP-Lung05 trial met its primary endpoint of progression-free survival, and the sac-TMT plus Keytruda combination also delivered a statistically significant improvement in overall survival versus Keytruda alone.
That is not routine pipeline noise. In pharma, survival data in a pivotal trial can reset revenue expectations fast, especially in non-small cell lung cancer, one of the biggest markets in oncology. A same-day market report tied MRK’s early move directly to that result, with shares up nearly 4.7% in morning trading.
There is also a strategic layer here. Sac-TMT is an antibody-drug conjugate developed with Kelun-Biotech, and the positive result shows Merck is building new combinations around Keytruda instead of treating it like a mature asset on autopilot. In plain English, the company is trying to turn one blockbuster into a broader oncology platform.
How Keytruda Sales and Merck Financials Support the Rally
The financial backdrop helps explain why the market reacted so quickly. In Q1 2026, Merck posted $16.3B in total sales, up 5% year over year. More important, Keytruda and Keytruda Qlex brought in $8.0B, up 12% from a year earlier.
That means roughly half of the company’s quarterly revenue came from the Keytruda franchise. So when Merck reports new evidence that Keytruda can win in another major treatment setting, the stock tends to react with more force than a typical drugmaker headline would produce.
Merck also raised its 2026 outlook after first-quarter results. The company lifted its sales guidance midpoint to a range of $65.8B to $67.0B and raised non-GAAP EPS guidance to $5.04 to $5.16. That matters because today’s clinical win lands on top of an already improving operating picture, not a shaky one.
There are soft spots in the story. Gardasil sales fell 22% in Q1 to $1.07B, hurt by weak demand in China. Even so, the market is clearly choosing to focus on oncology today, where Merck has more pricing power, more strategic depth, and a cleaner long-term growth path.
What MRK Valuation and Market Position Say After the Move
At $121.84, MRK is trading close to its 52-week high of $124.2199. That is an important detail. Stocks near highs do not get much room for excuses, so fresh positive data has to be real enough to justify another leg up. Today’s move says traders and longer-term investors see this trial as more than a headline pop.
Merck’s market cap sits at $300.92B, its dividend yield is 2.90%, and the stock trades at a P/E of 32.6423. That valuation is not cheap in a vacuum. However, it can hold up if the company keeps proving that its oncology engine has more runway than the market feared.
Analyst positioning adds another layer of support. The consensus rating is Buy, with 25 buy ratings, 11 holds, and 1 sell. The consensus price target is $129.31, with a high target of $150. Those targets were set before today’s move, which means the stock still trades below the broader analyst midpoint even after the rally.
Merck also has a habit of beating earnings expectations. It has beaten consensus in six straight reported quarters, including a 14.7% EPS surprise on April 30, 2026. That kind of consistency does not guarantee upside, but it does make investors more willing to pay up when a major pipeline event breaks in the company’s favor.
Why Merck's Oncology Pipeline Matters Beyond One Trial
Today’s catalyst did not arrive in isolation. Earlier this month, Merck said it would present more than 100 abstracts across over 25 cancer types at ASCO 2026. On May 18, the company also reported that TroFuse-005 met primary endpoints in advanced or recurrent endometrial cancer, with overall survival and progression-free survival benefits for sac-TMT.
Taken together, those updates strengthen the case that sac-TMT is becoming a meaningful asset inside Merck’s oncology pipeline. That matters because one of the market’s biggest concerns around Merck has been concentration risk around Keytruda. A stronger ADC platform gives the company another way to keep cancer growth alive, even as investors think ahead to future patent cliffs.
News sentiment also supports the move. MRK carries a 7-day sentiment score of 0.7407, with the broader 30-day and 90-day readings also strongly positive. Sentiment alone does not move a $300B stock. But positive sentiment paired with hard clinical data can act like dry wood meeting a spark.
One trading note deserves care. The stock data snapshot shows relative volume at 0.8x versus its 200-day average, so this is not an all-out volume stampede. Still, for a defensive mega-cap pharma name, a 5.14% single-day gain is significant on its own. Price is doing the loudest talking.
Merck’s rally looks tied to a specific and credible catalyst: positive Phase 3 lung cancer data for sac-TMT plus Keytruda. With Keytruda sales still expanding, full-year guidance moving higher, and the oncology pipeline gaining depth, the market is rewarding MRK for showing that its core franchise still has room to grow.
For investors, the practical takeaway is simple. Today’s move looks less like a defensive-stock bounce and more like a pipeline-driven rerating, which gives Merck a stronger case as both a quality healthcare holding and an oncology growth story.
MRK is up because Merck reported positive Phase 3 OptiTROP-Lung05 data in advanced lung cancer. The trial showed improved survival for a sac-TMT plus Keytruda combination versus Keytruda alone.
+Should I buy MRK stock now?
The article supports a constructive view because Merck has strong oncology momentum and raised guidance. Still, the stock is near its 52-week high, so investors may want to buy gradually rather than chase the move.
+What does the lung cancer trial mean for Merck?
It suggests Merck can keep extending Keytruda through combination therapies, which helps reduce reliance on a single blockbuster. That strengthens the company’s long-term oncology growth case.
+Is Merck still a good dividend stock after this move?
Yes, Merck still offers a dividend yield near 2.9% and remains a large, defensive healthcare name. The rally is driven by growth potential, but the income profile is still part of the investment appeal.
Want the full picture on MRK?
Read the analyst-grade research report — charts, grades, and price targets.
